RNA interference (RNAi) is a powerful tool for studying gene function. We developed an inducible genetic element for short interfering RNA-mediated gene silencing. This system uses a tetracycline (Tet)-responsive derivative of the H1 promoter and the Tet repressor (TetR) for conditional expression of short hairpin RNA (shRNA) in HeLa cells. Promoter constructs were generated, which contain the Tet operator (TetO) derived from a prokaryotic Tet resistance transposon upstream and/or downstream of the TATA box. To quantify the response of controllable transcription units for shRNA expression, we examined the functional activity of polo-like kinase 1 (PLK1), a key component of mitotic progression, that is overexpressed in many human tumors. Cotransfection of plasmids for the expression of TetR and shRNA/PLK1 under the control of an H1 promoter-variant carrying TetO upstream of the TATA box did not alter PLK1 expression and proliferation properties of HeLa cells in the absence of doxycycline. Addition of the antibiotic led to marked downregulation of endogenous PLK1 accompanied by strong inhibition of cellular proliferation. Our data indicate that an inducible transcription system for shRNAs based on the human H1 promoter could be a versatile tool for controlled gene silencing in vitro.
Introduction
The discovery of RNA interference (RNAi) has deeply influenced our understanding of gene regulation in animals, plants and many fungi. Small RNAs are termed short interfering RNAs (siRNAs) or micro-RNA depending on their origin. They diminish gene expression by binding to complementary mRNA and thereby triggering mRNA elimination (RNAi) or arresting mRNA translation (Carrington and Ambros, 2003; Denli and Hannon, 2003) . A third mechanism for gene silencing was recently observed in fission yeast: normal euchromatic (decondensed) genes can be direct targets of RNAi-dependent heterochromatin formation (Schramke and Allshire, 2003) . For the knock down of genes, siRNAs have been introduced into mammalian cells by transient transfection of synthetic doublestranded RNA (Elbashir et al., 2001; Spankuch and Strebhardt, 2004b) . On the other hand, Pol III (RNA polymerase III)-based promoters that trigger the synthesis of a large variety of small nuclear and cytoplasmic noncoding RNAs in higher eukaryotes have been used to drive the expression of siRNA and shRNA (small hairpin RNA) that are further processed to siRNAs (Lobo et al., 1990; Hannon et al., 1991; Chong et al., 2001; Brummelkamp et al., 2002; Paddison et al., 2002; Sui et al., 2002) . These siRNA expression vectors can be stably introduced into cells either as selectable plasmids or as viral vectors. The major advantage of the Pol III system is its high level of activity (approximately 4 Â 10 5 transcripts per cell) and the fact that it does not add additional nucleotides to the transcript that might affect functional activity. Beyond the family of Pol III-driven transcription units, the H1 promoter regulates the expression of H1 RNA, the RNA component of the human nuclear RNase P. The structures of Pol III promoters fall into three classes. In type III genes, like the H1 gene, sequence elements that are required for the transcription are found entirely in the 5 0 -flanking region. The H1 promoter comprises four cis-acting elements within a stretch of 100 bp of the 5 0 -flanking sequence: the TATA box (pos. À26 to À31 relative to the transcription start site), the PSE (proximal sequence element; pos. À51 to À68) and DSE (distal sequence element; pos. À69 to À100) containing an octamer motif, and a Staf binding site (Hannon et al., 1991; Myslinski et al., 2001) . In contrast to the U6 promoter that belongs also to type III of the Pol III family showing a distance of approximately 150 bp between the DSE and PSE element, a direct juxtaposition of the Staf binding and the PSE element is found in the H1 promoter making the H1 RNA gene unique. A mutational analysis has demonstrated that both the octamer sequence and the Staf binding site contribute to full promoter activity. In addition, DSE-and PSEbound factors seem to contact each other (Murphy et al., 1989; Danzeiser et al., 1993; Mittal et al., 1996) .
However, constitutive expression of inhibitory transcripts such as antisense DNA/RNA or siRNA by Pol II (RNA polymerase II) or Pol III promoters cannot be used if the target gene is essential for survival of cells. Thus, multiple attempts have been made to trigger gene activity by various inducible eukaryotic promoters responsive to heavy metal ions, heat-shock proteins or hormones (Hynes et al., 1981; Lee et al., 1981; Brinster et al., 1982; Mayo et al., 1982; Nouer, 1991) . Still, most inducible promoter constructs analysed up to date have suffered from the leakiness of the inactive state or from pleiotropic effects caused by the inducing mechanisms themselves. Most of these expression systems are based on the Pol II transcriptional system, which is specific for the transcription of mRNA. To control Pol II-based expression, a regulatory system was designed containing elements of the tetracycline (Tet) resistance operon encoded in Tn10 of Escherichia coli. The most prominent approach uses a fusion of the Tet repressor (TetR) with the activating domain of virion protein 16 of herpes simplex virus to generate a Tet-controlled transactivator (Gossen and Bujard, 1992; Gossen et al., 1995) . This chimeric protein TetR-VP16 strongly enhances transcription from minimal promoters on binding to the Tet operator (TetO) sequence.
In the present study, we set out to develop Tetinducible derivatives of the H1 promoter to drive shRNA expression targeted to the mRNA of polo-like kinase 1 (PLK1). The serine/threonine kinase PLK1 that is highly conserved from yeasts to humans plays a leading role for mitotic progression, in particular, control of the G 2 /M transition, the anaphase-promoting complex and cytokinesis (Blagden and Glover, 2003; Watanabe, 2003) . PLK1 expression is elevated in neoplastic tissues and has prognostic potential in a broad range of human tumors (Holtrich et al., 1994; Yuan et al., 1997; Strebhardt, 2001) . The aim of this project is to regulate PLK1 expression in cancer cells. Quantitative features of different promoter constructs such as the extent of inactivation and the kinetics of the on-/off-state need to be defined to evaluate the usefulness of this regulatory system. Inducible gene silencing via RNAi can be of utmost importance for the analysis of PLK1 in cultured cancer cells and for the future generation of transgenic animals with conditional PLK1 expression.
Results
Generation of Tet-responsive derivatives of the human H1 promoter for the expression of shRNA targeted to PLK1
For the generation of Tet-inducible forms of the H1 promoter, three derivatives were constructed. A palindromic operator sequence from the tet operon control region, called TetO (Hillen et al., 1984) for the occupation by the TetR, was inserted adjacent to the TATA box (Figure 1a and b purpose, we linked all H1 promoter constructs to a 19-bp PLK1-derived sequence that, when transcribed, forms an shRNA containing a 19-bp stem and a 9-bp loop, which is further processed to siRNA (Figure 1b and c). A termination sequence was included, which consists of five thymidine nucleotides. Two uracil nucleotides are predicted to constitute the 3 0 -end of the corresponding shRNA. Vectors for the expression of PLK1-specific shRNA were generated and named according to the human H1 promoter-derivative inserted: pUS, pDS and pUS/DS. In addition, constructs were produced that contain the wild-type H1 promoter constitutively driving the expression of PLK1-specific shRNA (phH1/shRNAPLK1) or a mismatched PLK1 sequence (phH1/shRNAPLK1MM) as control for subsequent transfections.
Impact of doxycycline (Dox) on the function of inducible H1 promoter variants
We examined the dose-response for Dox, a Tet derivative, which was previously shown to be a very efficient effector for TetR (Gossen et al., 1995) . In the absence of the synthetic regulator Dox, TetR binds to its operator and prevents expression of the shRNA transcripts by RNA polymerase III (Figure 1b) . To quantify the responses to Dox, we cotransfected HeLa cells with a plasmid including the open-reading frame for TetR under the control of a CMV (cytomegalovirus) promoter and a vector containing one of the H1 promoter derivatives driving the expression of shRNA targeted to PLK1. To evaluate the response of different promoter constructs to Dox, PLK1 expression was analysed by Northern and Western blotting. At 96 h after transfection with a vector containing the wild-type H1 promoter driving the expression of shRNA/PLK1, the level of PLK1 mRNA was significantly inhibited to 25% compared to the mismatched sequence shRNA/ PLK1MM (Po0.001) (Figure 2a , lanes 1 and 2). In exponentially growing cells, PLK1 mRNA expression was found to be the same as in mismatched shRNAPLK1MM-expressing cells, indicating that the introduction of certain mismatches completely abrogates the silencing capacity of PLK1-specific shRNAs (data not shown).
For the analysis of different promoter variants (US, DS or US/DS type), HeLa cells were transfected, and 24 h after transfection, cells were selected for 72 h in hygromycin B and G418. In addition, 24 h after transfection, Dox was added, and 72 h later, pUS-, pDS-and pUS/DS-transfected cells showed various extents of reduction of PLK1 mRNA expression, to 27-56% of the levels in cells expressing shRNA/PLK1MM (Po0.001 for all three promoter variants) ( Figure 2a , lanes 4, 6 and 8). In the absence of Dox cells transfected with pUS, pDS or pUS/DS showed higher PLK1-transcript levels, suggesting that the antibiotic increases the expression of PLK1-specific shRNA via TetR ( Figure 2a , lanes 3, 5 and 7). The promoter variant of the DS type showed the most pronounced leakiness in the absence of Dox (Figure 2a , lane 5). For the US/DS type promoter, only a small difference between the induced and noninduced state was measured (P ¼ 0.08). In the case of the US and DS type, repression of TetR by Dox was statistically significant compared to the uninduced state (Po0.01) (Figure 2a , lanes 3-6).
We next inspected whether the shRNA/PLK1-mediated decrease in PLK1 mRNA in HeLa cells was associated with a reduction of protein levels 96 h after transfection. Just as all three promoter types driving the expression of shRNA/PLK1 led to a downregulation of PLK1 mRNA after induction with Dox at a concentration of 5 mg/ml compared to cells transfected with phH1/ shRNAPLK1MM expressing a mismatched version, a significant silencing of the 68-kDa PLK1 protein expression was observed ( Figure 2b , lanes 3-8). After induction with Dox, PLK1 protein expression was reduced to levels of 62% (Po0.001) by pUS, to levels of 22% (Po0.001) by pDS and to levels of 50% (Po0.01) by pUS/DS compared to the mismatched sequence.
The aim of the current investigation was to identify an inducible promoter that shows little leakiness under noninduced conditions and considerable downregulation of PLK1 expression by shRNA/PLK1 following the addition of Dox. Northern and Western blot evaluations revealed that the promoter of the DS type that encompasses TetO downstream of the TATA box showed the most intense leakiness to 45% in the noninduced state compared to the level of PLK1 protein after transfection of cells with phH1/shRNAPLK1MM. Therefore, the promoter of the DS type that did not meet the desired criteria was excluded from future studies.
Analysis of the dose-dependent activity of Dox-responsive derivatives of the human H1 promoter H1 promoter variants showing low levels of reduction of PLK1 mRNA and protein in the noninduced state (US and US/DS type) were further studied in detail. HeLa cells transfected with pUS or pUS/DS were analysed for PLK1 expression by Northern blot analysis as the doseresponse after treatment with Dox. For comparison of H1 promoter variants, we started the study by analysing mRNA levels in US/DS type-transfected cells that had previously exhibited a medium degree of leakiness. In Dox-free medium, a reduction of PLK1 mRNA to 60% was observed (Figure 3a, lane 3) . With increasing concentrations of the antibiotic, a decrease of the PLK1 mRNA was observed leading to a strong reduction of the PLK1 mRNA to a level of 8% (Po0.001) at 10 mg/ml Dox compared to cells expressing shRNA/PLK1MM (Figure 3a, lanes 4-7) . The observation that 10 mg/ml Dox were needed for efficient knockdown of PLK1 transcripts might correlate to high levels of TetR expressed from the CMV promoter requiring high concentrations of the antibiotic. To find out whether silencing of transcripts translates also to diminished levels of PLK1 protein, we performed Western blot studies (Figure 3b) . In pUS/DS-transfected cells cultured without Dox PLK1 protein was decreased to 52% compared to the PLK1 protein expression after transfection with phH1/shRNAPLK1MM (Po0.01, Figure 3b , lane 3). After induction with 10 mg/ml Dox, PLK1 protein was statistically significantly reduced to 2% compared to the PLK1 protein expression after transfection with phH1/shRNAPLK1MM (Po0.001, Figure 3b, lane 7) .
Subsequently, the H1 promoter of the US type, which showed the lowest degree of leakiness compared to both other variants, was subjected to functional analysis. Expression of shRNA/PLK1 under the control of the US type downregulated PLK1 mRNA levels clearly in the presence of Dox (Figure 4a, lane 4-7) . At increasing concentrations of Dox (1-10 mg/ml), a gradual decrease of PLK1 expression was observed starting at 80% in the noninduced state (Figure 4a , lane 3) and descending to 14% (Po0.001, Figure 4a , lane 7) at a concentration of 10 mg/ml Dox compared to cells transfected with phH1/ shRNAPLK1MM (Figure 4a, lanes 3-7) . Whether silencing of PLK1 mRNA expression by the US type driving the synthesis of shRNA/PLK1 correlated to a downregulation of the 68-kDa PLK1 protein was explored next. HeLa cells were transfected with pUS or with phH1/shRNAPLK1MM. At 96 h after the beginning of transfection, the level of PLK1 protein was determined by Western blotting. Just as HeLa cells that were transfected with pUS and induced with 10 mg/ ml showed a strong reduction in PLK1 mRNA levels, cells showed a statistically significant reduction of PLK1 protein to 22% (Po0.001) 96 h after transfection as compared with control cells transfected with phH1/ shRNAPLK1MM (Figure 4b, lane 7) .
To determine the functional significance of PLK1 mRNA downregulation in US type-transfected cells, we While induction with 5 mg/ml Dox led to a slight reduction of substrate phosphorylation, application of 10 mg/ml Dox caused a strong reduction in kinase activity compared to noninduced control cells ( Figure 5 ).
Conditional silencing of PLK1 leads to the inhibition of proliferation in cancer cells
Previous inquiries demonstrated that RNAi-or antisense-based downregulation of PLK1 expression inhibits the proliferation of cancer cells irreversibly (Spankuch-Schmitt et al., 2002a, b; Liu et al., 2002 Liu et al., , 2003 Spankuch et al., 2004a) . We addressed the question as to whether the conditional shRNA/PLK1 system is suitable to regulate the proliferation of cancer cells. The promoter construct (US type) that exhibited the desired properties, (i) low degree of leakiness in the absence of Dox and (ii) strong reduction of PLK1 expression after the administration of the antibiotic, was further characterized in detail. As positive control for the inhibition of cell proliferation, we used phH1/ shRNAPLK1 for transfection of HeLa cells. Expression of shRNA/PLK1 under the control of the wild-type H1 promoter strongly inhibited the increase of HeLa cell proliferation to 16.3% compared with cells transfected with plasmid phH1/shRNAPLK1MM expressing the mismatched control shRNA/PLK1 (Po0.05). These mismatched control plasmids did not reduce the proliferation of cells compared to untreated cells. The addition of Dox (5 mg/ml) itself to nontransfected cells (data not shown) or to mismatched shRNA/PLK1MM-expressing cells had no significant effect on HeLa cell proliferation in this assay ( Figure 6 ). Cells transfected with pUS showed no statistically significant reduction in proliferation in the absence of Dox (P ¼ 0.1). The addition of Dox to HeLa cells expressing shRNA/ PLK1 under the control of the US-type promoter led to a significant inhibition of cell proliferation to 32.8% compared to the cell number of phH1/ shRNAPLK1MM-transfected cells (Po0.05). This result is consistent with the Dox-dependent inhibition of PLK1 expression leading to a strong antiproliferative effect in HeLa cells.
To test whether inducible downregulation of PLK1 expression using H1 promoter (US-type)-driven expression of shRNA/PLK1 is sufficient to induce apoptosis in cancer cells, transfected HeLa cells were stained with annexin V and propidium iodide (PI). At 72 h after the addition of Dox, flow cytometric measurements of cells transfected with plasmid pUS revealed an increase of HeLa cells that were annexin V positive (early stage of apoptosis) and HeLa cells that were annexin-and PI double positive (late stage of apoptosis), suggesting that the inducible induction of shRNA expression silences PLK function to an extent that induces apoptosis in HeLa cells (data not shown). 
Discussion
In this study, we describe the functional analysis of different inducible human H1 promoter variants driving the expression of shRNA targeted to PLK1. For the first time, the proliferative control of cancer cells via an inducible RNAi-based approach could be demonstrated. While shRNA/PLK1 under the control of the noninduced H1 promoter (US type) had only a very weak influence on PLK1 expression leaving the proliferation of HeLa cells untouched, 72 h after the addition of Dox PLK1 mRNA and protein levels decreased significantly leading to a strong inhibition of cell proliferation.
Different prokaryotic repressor-operator systems can be utilized for the control of Pol II promoters (Kassavetis et al., 1990 ). Dingermann and co-workers demonstrated that a Pol III-regulated system can be controlled in Saccharomyces cerevisiae by the bacterial TetR-TetO system (Dingermann et al., 1992a, b) and Luukkonen et al. revealed that the U6 snRNA promoter of yeast can be regulated by the Lac repressor-operator system (Luukkonen and Seraphin, 1998) . Recent approaches investigated whether the prokaryotic TetOTetR system is useful for the regulation of Pol III-based expression in mammalian cells (Ohkawa and Taira, 2000; van de Wetering et al., 2003; Wiznerowicz and Trono, 2003) . In particular, the U6 promoter has been analysed in detail (Ohkawa and Taira, 2000) . Insertion of TetO into an U6 promoter at different positions upstream of the transcription start site had a differential effect on its leakiness in the absence of Tet or activation in the presence of the drug: replacing the connecting sequence between the TATA box and PSE element by an operator element resulted to 80% of the activity of the wild-type promoter after the addition of Dox and transcriptional activity was completely repressed in the noninduced state (Ohkawa and Taira, 2000) .
Still, the use of the U6 promoter for the highfrequency expression of shRNA seems to be accompanied by certain disadvantages: the most profound cellular response to introducing increasing doses of an active U6 promoter is not a decrease in endogenous U6 transcription production, but rather an increase in endogenous U6 transcript degradation (Noonberg et al., 1996) . This response represents a specific mechanism regulating total U6 RNA, suggesting a hitherto unrecognized U6-specific intracellular regulatory mechanism, through which overaccumulation of U6 small RNA is prevented. Owing to this phenomenon that might block high-level expression of shRNA in target cells, we focused on the exploration of the H1 promoter. H1 belongs to the family of Pol III promoters and is characterized by an unusual compact organization within 100 bp of 5 0 -flanking sequences. While in the U6 promoter, the DSE element (Octamer and Staf binding site) is separated from the PSE element by a stretch of 83 bp; in the H1 promoter, both elements are adjacent. We investigated the impact of different locations of the operator sequence within the H1 promoter on the functional activity for the expression of shRNA. The analysed constructs differed in the location of TetO relative to the TATA box upstream of the transcription start site in the H1 promoter. In the absence of the antibiotic different promoter derivatives showed varying leakiness. Compared to the H1 promoter of the US type, shRNA/PLK1 driven by the DS type and US/DS type led to considerable reduction of PLK expression in the noninduced state, which could be an important disadvantage for the functional analysis of genes that are essential for cell survival.
We focused our study on the analysis of the promoter of the US type, because our evaluation revealed that cells transfected with the H1 promoter of the US type under noninduced conditions showed a PLK1 expression that is similar to the levels in HeLa cells that express the mismatched shRNA/PLK1MM under the control of the wild-type H1 promoter as negative control. Our data suggest that binding of the repressor to an operator located between the TATA box and PSE element closes the H1 promoter tightly preventing shRNA/PLK expression completely. This observation is in line with previous experiments, which had revealed that the sequence substitution in the region between the PSE and the TATA motif (S-47/-40) resulted in an important reduction in RNA synthesis, both in vitro and in vivo (Myslinski et al., 2001) . This study suggested that this sequence can influence per se, perhaps by inducing a special conformation of the DNA. Considering the functional key role of this motif for the activity of the H1 promoter, it seems to be favorable for the regulation of transcriptional potency. Thus, the US type fulfills two important requirements (low leakiness and strong inhibition of PLK expression after induction with Dox) for the generation of transgenic animals characterized by controlled expression of PLK1. For this purpose, ongoing trials are exploring conditional expression in murine embryonic stem cells for the future control of RNAi-based gene silencing in mice. 
Materials and methods

Cloning of expression constructs
The promoter of the human gene expressing H1 RNA (GenBank Accession no. X16612) was amplified using genomic DNA from HeLa S3 cells with the sense primer 5 0 -GTGAGG GACACTCGAGTGGCGCCCTGCAATATT-3 0 and the antisense primer 5 0 -TCCGCCCTATGGATCCGAGAAGCTTCA TACAGAA-3 0 . The amplified fragment was digested with XhoI and HindIII and ligated into a pH1 vector, which is derived from a pEGFP-C2 vector (BD Biosciences, Heidelberg, Germany).
Different types of Tet-inducible H1 promoters containing TetO sequences were generated by PCR using the wild-type H1 promoter as template. Generation and amplification of different Tet-inducible H1 constructs were carried out with the sense primer 5 0 -GTGAGGGACACTCGAGTGGCGCCC TGCAATATT-3 0 and the antisense primers as follows: 0 . All fragments were digested with XhoI and BamH1 and ligated into the XhoI-BamHI of the pH1 vector.
shRNAs were designed using our own computer software (Yves Matthess, unpublished method). The template for the expression of shRNA against PLK1 was formed by annealing of the sense oligonucleotide 5 0 -GTCGGATCCGTGCTTC GAGATCTCGGACTTCATATGGGTCCGAGATCTCGA AGCACTTTTTAAGCTTAGT-3 0 and the antisense oligonucleotide 5 0 -ACTAAGCTTAAAAAAGTGCTTCGAGATCT CGGACCCATATGAAGTCCGAGATCTCGAAGCACGG ATCCGAC-3 0 . For the mismatched shRNA, the sense oligonucleotide 5 0 -GTCGGATCCGTGCACTGAGATCTCG GACTTCATATGGGTCCGAGATCTCAGTGCACTTTTT AAGCTTAGT-3 0 and the antisense oligonucleotide 5 0 -AC TAAGCTTAAAAAGTGCACTGAGATCTCGGACCCAT ATGAAGTCCGAGATCTCAGTGCACGGATCCGAC-3 0 were annealed. After digestion with BamH1 and HindIII, the fragment used for the expression of shRNA/PLK1 was ligated into the BamHI-HindIII site of the plasmid containing the wild-type H1 promoter and plasmids containing different H1 promoter variants to generate the following recombinant plasmids:
(1) ptet O-T-hH1/shRNAPLK1 (pUS), (2) ptet T-O-hH1/shRNAPLK1 (pDS) and (3) ptet O-T-O-hH1/shRNAPLK1 (pUS/DS).
The gene coding for TetR was amplified from Tn.10 of E. coli with the sense primer 5 0 -GTCAACAAAAATTAGCTAG CAATGATGTCTAGAT-3 0 and the antisense primer 5 0 -CGGAAAAACTCGAGCGATCGTTTAAGACCCACT-3 0 . After digestion with NheI and XhoI, the fragment was inserted into the NheI-XhoI site of the pcDNA3.1Hygro þ vector (Invitrogen GmbH, Karlsruhe, Germany), which contains the hygromycin B resistance gene.
Cell culture and transfection
HeLa cells were obtained from DSMZ (Braunschweig, Germany) and cultured in MEM-Eagle (Sigma, Taufkirchen, Germany) containing 10% Tet system-approved fetal calf serum (PAA Laboratories GmbH, Pasching, Austria), L-glutamine (Invitrogen GmbH, Karlsruhe, Germany) and penicillin-streptomycin (Invitrogen GmbH, Karlsruhe, Germany).
HeLa cells were transfected with Fugene 6 transfection reagent (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. For each transfection, a mixture containing H1 vector and TetR-expressing plasmid at a ratio of 2:3 was used. Selection of transfected cells with geneticin (G418; Invitrogen GmbH, Karlsruhe, Germany; 600 mg/ml) and hygromycin B (BD Biosciences, Heidelberg, Germany; 100 mg/ml) started 24 h after transfection. Expression from inducible promoters was induced by the addition of Dox (Sigma, Taufkirchen, Germany) at different concentrations (1-10 mg/ml) beginning simultaneously with selection 24 h after transfection. Dox-containing medium was replaced every 24 h. Each transfection experiment was performed at least in triplicate.
Cell lysis and Western blot analysis
At 72 h after the selection of transfected cells, extracts were prepared as described (Bohme et al., 1996) . Western blots were performed as described (Spankuch-Schmitt et al., 2002a) . Membranes were incubated with monoclonal antibodies against PLK1 (1 : 300; Santa Cruz Biotechnology Inc., Heidelberg, Germany) and b-actin (1 : 200 000; Sigma, Taufkirchen, Germany) and with goat anti-mouse serum (1 : 2000; Santa Cruz Biotechnology Inc., Heidelberg, Germany) and visualized as described (Spankuch-Schmitt et al., 2002a) . Standardization was performed as described (Spankuch et al., 2004a) . Resulting PLK1 protein levels were presented as a percentage of PLK1 protein levels in cells treated with control mismatched plasmids.
Kinase assays
To assay PLK1 kinase activity, cells were lysed and PLK1 was immunoprecipitated from lysates using monoclonal PLK1 antibodies as described (Spankuch-Schmitt et al., 2002a) . In brief, for each immunoprecipitation 800 mg of total protein was incubated with 0.5 mg of antibody for 1 h at 41C on a rotator. The immunoprecipitates were incubated with 0.5-1 mg of substrate (the cytoplasmic retention signal within human cyclin B1 (Toyoshima-Morimoto et al., 2001; Yuan et al., 2002) ) and with 2 mCi of [g 32 -P]ATP for 30 min at 371C in kinase buffer. Products from the kinase assays were fractionated on SDS-polyacrylamide (12%) gels, and phosphorylated substrate was visualized by autoradiography. After visualization, gels were stained with Coomassie blue to assay for equal loading of substrate. An equal amount of immunoprecipitates was subjected to Western blot analysis to confirm equal loading of PLK1 protein in kinase reactions.
Preparation of RNA and Northern blot analysis
At 72 h after selection of transfected HeLa cells, total RNA was isolated using RNeasy Mini Kit according to the manufacturer's protocol (Qiagen, Hilden, Gemany). Probes for Northern blots were generated by radiolabeling antisense PLK1 strands as described (Spankuch-Schmitt et al., 2002a) . Northern blotting, hybridizations and standardization were carried out as described previously (Spankuch et al., 2004a) . 
Determination of cell proliferation
The growth rate of 6 Â 10 5 cells was determined by counting cells at 0, 24, 48, 72, 96 , and 120 h after the beginning of induction using a hemacytometer. At 192 h after transfection, the number of control cells (incubated with plasmids constitutively expressing the mismatch sequence) was determined as reference to calculate the percentage of proliferating cells.
Determination of apoptosis
At 120 and 144 h after transfection, cells were harvested and the percentage of apoptotic cells was determined by incubation with annexin V according to the supplier's instructions (MoBiTech, Go¨ttingen, Germany).
Statistical methods
All experiments were performed at least in triplicate. Standardization and statistics were performed as described (Spankuch-Schmitt et al., 2002a) . For t-tests, all transfected cells were compared to cells transfected with plasmids expressing the mismatched sequence.
